256 related articles for article (PubMed ID: 28883286)
21. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
22. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
23. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
[TBL] [Abstract][Full Text] [Related]
24. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
25. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Jelinek T; Kryukova E; Kufova Z; Kryukov F; Hajek R
Hematol Oncol; 2017 Dec; 35(4):408-419. PubMed ID: 27647123
[TBL] [Abstract][Full Text] [Related]
27. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lonial S; Boise LH
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
[TBL] [Abstract][Full Text] [Related]
28. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
Steinmetz TH; Singh M; Lebioda A; Fink L; Schoehl M; Rieth A; Gonzalez-McQuire S; Engelhardt M
J Med Econ; 2021; 24(1):114-122. PubMed ID: 33390079
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
30. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
31. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
32. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
33. The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Zangari M; Suva LJ
Bone; 2016 May; 86():131-8. PubMed ID: 26947893
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib in multiple myeloma: a practice guideline.
Kouroukis CT; Baldassarre FG; Haynes AE; Imrie K; Reece DE; Cheung MC;
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):110-9. PubMed ID: 24321107
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
36. Comparative mechanisms of action of proteasome inhibitors.
Wang M
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
[TBL] [Abstract][Full Text] [Related]
37. Nonselective proteasome inhibitors in multiple myeloma and future perspectives.
Gavriatopoulou M; Malandrakis P; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Opin Pharmacother; 2022 Feb; 23(3):335-347. PubMed ID: 34761710
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
McCarthy PL; Einsele H; Attal M; Giralt S
Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]